Literature DB >> 15290854

Technetium-99m-Labeled N-(2-hydroxypropyl) methacrylamide copolymers: synthesis, characterization, and in vivo biodistribution.

Amitava Mitra1, Anjan Nan, Hamidreza Ghandehari, Edwina McNeill, Justin Mulholland, Bruce R Line.   

Abstract

PURPOSE: To synthesize novel technetium-99m (99mTc)-labeled N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers and characterize the effect of charge and molecular weight on their biodistribution in SCID mice.
METHODS: Electronegative and neutral 7-kDa, 21-kDa, and 70-kDa HPMA copolymers containing a 99mTc chelating comonomer, bearing N-omega-bis(2-pyridylmethyl)-L-lysine (DPK), were synthesized by free-radical precipitation copolymerization. The copolymers were labeled via 99mTc tricarbonyl chelation to DPK-bearing comonomer. They were characterized by side-chain content, molecular weight, molecular weight distribution, radiochemical purity, and labeling stability. Scintigraphic images were obtained during the first 90 min and at 24 h postintravenous injection in SCID mice. At 24 h, organ radioactivity was determined from necropsy tissue counting.
RESULTS: 99mTc-labeled HPMA copolymers showed greater than 90% stability over a 24-h challenge with cysteine and histidine. Scintigraphic images and the necropsy data showed that the negatively charged copolymers were eliminated from the body significantly faster than the neutral copolymers in a size-dependent manner.
CONCLUSIONS: To facilitate clinical scintigraphic imaging, stable chelation of 99mTc may be achieved by incorporation of a DPK-bearing comonomer into the HPMA backbone. Electronegative and neutral 99mTc-labeled HPMA copolymers of 7, 21, and 70 kDa show significant variation in organ biodistribution in SCID mice. 99mTc-labeled HPMA copolymers could be used as diagnostic agents and to study pharmacokinetics of delivery systems based on these copolymers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15290854     DOI: 10.1023/b:pham.0000033001.49737.b7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

Review 1.  Current use and future potential of organometallic radiopharmaceuticals.

Authors:  Roger Schibli; P August Schubiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08-06       Impact factor: 9.236

2.  Influence of the denticity of ligand systems on the in vitro and in vivo behavior of (99m)Tc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules.

Authors:  R Schibli; R La Bella; R Alberto; E Garcia-Garayoa; K Ortner; U Abram; P A Schubiger
Journal:  Bioconjug Chem       Date:  2000 May-Jun       Impact factor: 4.774

3.  Comparison of the stability of technetium-labeled peptides to challenge with cysteine.

Authors:  M A Stalteri; S Bansal; R Hider; S J Mather
Journal:  Bioconjug Chem       Date:  1999 Jan-Feb       Impact factor: 4.774

Review 4.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.

Authors:  G B Fields; R L Noble
Journal:  Int J Pept Protein Res       Date:  1990-03

5.  Surface properties of copolymers of alkyl methacrylates with methoxy (polyethylene oxide) methacrylates and their application as protein-resistant coatings.

Authors:  J H Lee; P Kopeckova; J Kopecek; J D Andrade
Journal:  Biomaterials       Date:  1990-09       Impact factor: 12.479

6.  Organometallic 99mTc-aquaion labels peptide to an unprecedented high specific activity.

Authors:  A Egli; R Alberto; L Tannahill; R Schibli; U Abram; A Schaffland; R Waibel; D Tourwé; L Jeannin; K Iterbeke; P A Schubiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

7.  [(99m)Tc]MAG(3)-mannosyl-dextran: a receptor-binding radiopharmaceutical for sentinel node detection.

Authors:  D R Vera; A M Wallace; C K Hoh
Journal:  Nucl Med Biol       Date:  2001-07       Impact factor: 2.408

8.  Design of novel bioconjugates for targeted drug delivery.

Authors:  Zheng-Rong Lu; Jane-Guo Shiah; Shinji Sakuma; Pavla Kopecková; Jindrich Kopecek
Journal:  J Control Release       Date:  2002-01-17       Impact factor: 9.776

9.  Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier.

Authors:  L W Seymour; Y Miyamoto; H Maeda; M Brereton; J Strohalm; K Ulbrich; R Duncan
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

Review 10.  Imaging of angiogenesis: from microscope to clinic.

Authors:  Donald M McDonald; Peter L Choyke
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

View more
  14 in total

Review 1.  Endocytic mechanisms for targeted drug delivery.

Authors:  Lisa M Bareford; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

2.  Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation.

Authors:  Mark P Borgman; Tomika Coleman; Rohit B Kolhatkar; Sandra Geyser-Stoops; Bruce R Line; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2008-07-18       Impact factor: 9.776

3.  177Lu-labeled HPMA copolymers utilizing cathepsin B and S cleavable linkers: synthesis, characterization and preliminary in vivo investigation in a pancreatic cancer model.

Authors:  Sunny M Ogbomo; Wen Shi; Nilesh K Wagh; Zhengyuan Zhou; Susan K Brusnahan; Jered C Garrison
Journal:  Nucl Med Biol       Date:  2013-04-24       Impact factor: 2.408

4.  The influence of linker length on the properties of cathepsin S cleavable (177)Lu-labeled HPMA copolymers for pancreatic cancer imaging.

Authors:  Wen Shi; Sunny M Ogbomo; Nilesh K Wagh; Zhengyuan Zhou; Yinnong Jia; Susan K Brusnahan; Jered C Garrison
Journal:  Biomaterials       Date:  2014-04-19       Impact factor: 12.479

5.  Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers.

Authors:  Dong Wang; Monika Sima; R Lee Mosley; Jasmine P Davda; Nicole Tietze; Scott C Miller; Peter R Gwilt; Pavla Kopecková; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

6.  HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer.

Authors:  Nate Larson; Abhijit Ray; Alexander Malugin; Daniel B Pike; Hamidreza Ghandehari
Journal:  Pharm Res       Date:  2010-09-16       Impact factor: 4.200

7.  Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model.

Authors:  Ling-Dong Quan; Fang Yuan; Xin-Ming Liu; Jian-Geng Huang; Yazen Alnouti; Dong Wang
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

8.  HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluation.

Authors:  Bahar Zarabi; Anjan Nan; Jiachen Zhuo; Rao Gullapalli; Hamidreza Ghandehari
Journal:  Macromol Biosci       Date:  2008-08-11       Impact factor: 4.979

Review 9.  Poly(2-oxazoline)s as polymer therapeutics.

Authors:  Robert Luxenhofer; Yingchao Han; Anita Schulz; Jing Tong; Zhijian He; Alexander V Kabanov; Rainer Jordan
Journal:  Macromol Rapid Commun       Date:  2012-08-03       Impact factor: 5.734

10.  Riboflavin-targeted polymer conjugates for breast tumor delivery.

Authors:  Lisa M Bareford; Brittany R Avaritt; Hamidreza Ghandehari; Anjan Nan; Peter W Swaan
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.